NKTR · Categories · Coverage
NKTR - Analyst coverage initiated
Nektar Therapeutics (NKTR) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for NKTR
- UBS initiated coverage on Nektar Therapeutics with a new price targetUBS initiated coverage of Nektar Therapeutics with a rating of Neutral and set a new price target of $53.00
- Leerink Partners initiated coverage on Nektar Therapeutics with a new price targetLeerink Partners initiated coverage of Nektar Therapeutics with a rating of Outperform and set a new price target of $130.00
- Raymond James initiated coverage on Nektar TherapeuticsRaymond James initiated coverage of Nektar Therapeutics with a rating of Mkt Perform
- Canaccord Genuity initiated coverage on Nektar Therapeutics with a new price targetCanaccord Genuity initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $153.00
- Wedbush initiated coverage on Nektar Therapeutics with a new price targetWedbush initiated coverage of Nektar Therapeutics with a rating of Neutral and set a new price target of $70.00
- TD Cowen initiated coverage on Nektar TherapeuticsTD Cowen initiated coverage of Nektar Therapeutics with a rating of Buy
- Citigroup initiated coverage on Nektar Therapeutics with a new price targetCitigroup initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $102.00
- B. Riley Securities initiated coverage on Nektar Therapeutics with a new price targetB. Riley Securities initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $4.00
- H.C. Wainwright initiated coverage on Nektar Therapeutics with a new price targetH.C. Wainwright initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $6.50
- Piper Sandler initiated coverage on Nektar Therapeutics with a new price targetPiper Sandler initiated coverage of Nektar Therapeutics with a rating of Overweight and set a new price target of $7.00
- Rodman & Renshaw initiated coverage on Nektar Therapeutics with a new price targetRodman & Renshaw initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $2.00
- BofA Securities initiated coverage on Nektar Therapeutics with a new price targetBofA Securities initiated coverage of Nektar Therapeutics with a rating of Neutral and set a new price target of $18.00